A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

Clinical trial NCT06979076 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06979076
Sponsor: MingSight Pharmaceuticals, Inc
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

CLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)

Start date: 2026-07-01
Primary completion: 2028-09-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.